Details for Patent: 7,125,873

Title:	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Abstract:	The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Inventor(s):	Edmondson; Scott D (New York, NJ), Fisher; Michael H. (Ringoes, NJ), Kim; Dooseop (Westfield, NJ), Maccoss; Malcolm (Freehold, NJ), Parmee; Emma R. (Scotch Plains, NJ), Weber; Ann E (Scotch Plains, NJ), Xu; Jinyou (Scotch Plains, NJ)
Assignee:	Merck & Co., Inc. (Rahway, NJ)
Filing Date:	Jul 05, 2002
Application Number:	10/481,353
Claims:	1. A pharmaceutical composition comprising (1) a first compound of the formula: ##STR00024## or a pharmaceutically acceptable salt thereof; (2) a second compound selected from the group consisting of: (a) other dipeptidyl peptidase IV (DP-IV) inhibitors; (b) insulin sensitizers selected from the group consisting of (i) PPAR.gamma. agonists, other PPAR ligands, PPAR.alpha./.gamma. dual agonists, and PPAR.alpha. agonists, (ii) biguanides, and (iii) protein tyrosine phosphatase-1B (PTP-1B) inhibitors; (c) insulin or insulin mimetics; (d) sulfonylureas or other insulin secretagogues; (e) .alpha.-glucosidase inhibitors; (f) glucagon receptor agonists; (g) GLP-1, GLP-1 mimetics, and GLP-1 receptor agonists; (h) GIP, GIP mimetics, and GIP receptor agonists; (i) PACAP, PACAP mimetics, and PACAP receptor 3 agonists; (j) cholesterol lowering agents selected from the group consisting of (i) HMG-CoA reductase inhibitors, (ii) sequestrants, (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPAR.alpha. agonists, (v) PPAR.alpha./.gamma. dual agonists, (vi) inhibitors of cholesterol absorption, (vii) acyl CoA:cholesterol acyltransferase inhibitors, and (viii) anti-oxidants; (k) PPAR.delta. agonists; (l) antiobesity compounds; (m) ileal bile acid transporter inhibitors; and (n) anti-inflammatory agents; and (3) a pharmaceutically acceptable carrier. 2. The pharmaceutical composition of claim 1 wherein said biguanide is metformin. 3. The pharmaceutical composition of claim 1 wherein said second compound is a sulfonylurea. 4. The pharmaceutical composition of claim 1 wherein said PPAR.gamma. agonist is pioglitazone or rosiglitazone. 5. A method of treating Type 2 diabetes comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a first compound of the formula: ##STR00025## or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a second compound selected from the group consisting of: (a) other dipeptidyl peptidase IV (DP-IV) inhibitors; (b) insulin sensitizers selected from the group consisting of (i) PPAR.gamma. agonists, other PPAR ligands, PPAR.alpha./.gamma. dual agonists, and PPAR.alpha. agonists, (ii) biguanides, and (iii) protein tyrosine phosphatase-1B (PTP-1B) inhibitors; (c) insulin or insulin mimetics; (d) sulfonylureas or other insulin secretagogues; (e) .alpha.-glucosidase inhibitors; (f) glucagon receptor agonists; (g) GLP-1, GLP-1 mimetics, and GLP-1 receptor agonists; (h) GIP, GIP mimetics, and GIP receptor agonists; (i) PACAP, PACAP mimetics, and PACAP receptor 3 agonists; (j) cholesterol lowering agents selected from the group consisting of(i) HMG-CoA reductase inhibitors, (ii) sequestrants, (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPAR.alpha. agonists, (v) PPAR.alpha./.gamma. dual agonists, (vi) inhibitors of cholesterol absorption, (vii) acyl CoA:cholesterol acyltransferase inhibitors, and (viii) anti-oxidants; (k) PPAR.delta. agonists; (l) antiobesity compounds; (m) ileal bile acid transporter inhibitors; and (n) anti-inflammatory agents. 6. The method of claim 5 wherein said biguanide is metformin. 7. The method of claim 5 wherein said second compound is a sulfonylurea. 8. The method of claim 5 wherein said PPAR.gamma. agonist is pioglitazone or rosiglitazone.